Geneva Scientists Advance Diabetes Cure.

Scientists at the University of Geneva have announced a major breakthrough that could pave the way toward an insulin-free future for patients with type 1 diabetes.

Researchers from University of Geneva and Geneva University Hospitals have developed an innovative hydrogel called Amniogel, which has shown promising results in preclinical tests on mice.

The study, led by Professor Ekaterine Berishvili, focuses on improving the survival and function of insulin-producing cells after transplantation into the body. Traditional pancreatic islet transplants often face challenges such as immune rejection, inflammation, and poor blood supply, especially when placed in the liver.

Amniogel, derived from human amniotic membrane, helps create a supportive microenvironment for transplanted cells. It promotes the formation of a microvascular network before transplantation, allowing better integration with the host’s bloodstream.

Researchers say this “protective environment” enables the transplanted cells to function effectively and maintain normal blood glucose levels.

In experiments involving diabetic mice, small grafts using the hydrogel maintained stable blood sugar levels for at least 100 days without the need for external insulin injections.

This marks a significant step forward in the development of a bioartificial pancreas, a long-term goal in diabetes research aimed at reducing or eliminating the need for daily insulin therapy.

The next phase of research will focus on scaling up the technology, increasing graft size and quantity, and preparing for potential human clinical trials.

Beyond diabetes treatment, scientists believe the hydrogel platform could be adapted for other types of cell-based therapies, potentially opening new possibilities in regenerative medicine.